A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)

Published:2023-02-01 Issue:2 Volume:33 Page:67-87
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Kovalová Markéta¹^ORCID,Baraka Joseph Peter²,Mik Václav¹^ORCID,Jorda Radek¹^ORCID,Luo Lei²,Shao Hao²,Kryštof Vladimír¹³^ORCID

Affiliation:

1. Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic

2. College of Pharmaceutical Sciences, Southwest University, Chongqing, China

3. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic

Funder

European Union - Next Generation EU (National Institute for Cancer Research

Czech Science

Palacký University Olomouc

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2023.2195547

Reference126 articles.

1. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms

2. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery

3. The history and future of targeting cyclin-dependent kinases in cancer therapy

4. TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II

5. Targeting transcription cycles in cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7);European Journal of Medicinal Chemistry;2024-10

2. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors;Bioorganic Chemistry;2024-07

3. Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets;Molecular Cancer;2024-06-07

4. CDK7 in breast cancer: mechanisms of action and therapeutic potential;Cell Communication and Signaling;2024-04-11

5. Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway;British Journal of Cancer;2024-02-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3